Quarterly ResultApr 29, 2026, 04:31 PM
MDXG Q1 Net Sales -33.1% to $59M; Reports $(10.9)M Net Loss
AI Summary
MIMEDX Group reported a significant decline in Q1 2026, with net sales decreasing 33.1% to $59.0 million and a GAAP net loss of $(10.9) million, compared to a net income of $7.0 million in the prior year. This was primarily due to a 59.7% drop in Wound net sales following Medicare reimbursement changes, despite a 13.2% increase in Surgical net sales. The company also announced a cost reduction initiative, including a 15% workforce reduction, and launched new products while securing new distribution agreements.
Key Highlights
- Q1 2026 Net Sales decreased 33.1% to $59.0 million from $88.2 million YoY.
- Q1 2026 GAAP Net Loss was $(10.9) million, compared to $7.0 million net income YoY.
- Q1 2026 Diluted EPS was $(0.07), down from $0.05 YoY.
- Wound net sales declined 59.7% to $22.6 million due to Medicare reimbursement changes.
- Surgical net sales increased 13.2% to $36.4 million, driven by product line growth.
- Cash and cash equivalents stood at $159.8 million as of March 31, 2026.
- Announced April 2026 cost reduction initiative, reducing workforce by 15%, expecting $4 million in Q2 expenses.
- Paid $5.0 million for exclusive distribution rights for RegenKit®-Wound Gel.
Price Impact
More from MDXG